Background: Amlapitta is a lifestyle disorder caused due to vitiation of Pitta and Kapha by Ama. Objective: The objective was to assess the role of Doshik predominance in the management of Amlapitta. Materials and Methods: Patients who had fulfilled the inclusion criteria were registered primarily for this study. Out of them, those who were selected only by the presence of cardinal features of Amlapitta were allotted randomly in Group C-1 and Group C-2 and rest of them were allotted in Group A and B after diagnosed by typical features of Kapha and Pitta Dosha predominant Amlapitta and had been treated with Shunthikhanda and Vasakhanda Kushmandaka granules, respectively. Results: Regarding overall effect of therapy, marked positive improvement in Group A was 35.29%, in Group B, 26.47%, in Group C-1, 23.08%, and Group C-2, 16.67%. No improvement was observed only in Group C-1 (4.76%) and C-2 (5.56%). Complete remission (2.56%) was observed only in Group C-2 (5.56%) Discussion: Out of 112 registered patients with a mean age of 42 years, 107 had completed their treatment. Maximum patients were male (66.96%), Hindu (83.93%), married (94.64%), middle class (43.75%), and educated (93.75%) from Jangala Desha (96.43%) and used to take Viruddha Ahara (83.04%). Patients of Group A and Group B, who were diagnosed and treated according to the Doshik predominance, showed better improvement than of Group C-1 and Group C-2 where patients were diagnosed and treated as per the cardinal features of Amlapitta only. Conclusion: Treatment of disease according to Doshik predominance is more effective than of only cardinal features.
Introduction
According to Ayurvedic classics, Agni is responsible for Ayu (age), Varna (colour), Bala (power), Swasthya (health), Utsaha (excitement), Upachaya (digestion), Prabha, Oja and Teja [1] and Agni takes a pivot role in the etiopathogenesis of all human ailments. [2, 3] According to Acharya Charaka, indulging in Ajirna, Atibhojana (over eating), Vishama Bhojana (irregular diet), Asatmya (incompatible diet) and Sandushta Bhojana produces Shuktata due to Agni Dushti (impairment of Agni) followed by Ama and Amavisha which further develops Ajirna (indigestion) by vitiating Dosha. [4] Continuous indulgence in improper diet and erratic lifestyle basically aggravates Pitta Dosha which leads the disease into acute condition of Vidagdhajirna (indigestion) which due to ignorance inturn converts into Amlapitta in long run.
It is better to consider Amlapitta as a syndrome (acid reflux syndrome) [5] rather than a particular gastrointestinal disease due to the same causative factors with similar signs and symptoms as in Ayurvedic parlance closely resembles with gastritis, [6] non-ulcer dyspepsia, [7] hyperchlorhydria, [8] as well as hypochlorhydria [9] and in chronic stage, it may lead to gastric ulcer. Gastrointestinal disorders become lifestyle maladies when people shift their eating pattern toward ready-to-eat commercial junk meals from homemade food and adopt erratic lifestyles. According to the National Digestive Diseases Information Clearinghouse, the prevalence rate of gastritis in India is 10,572,391 and that of peptic ulcer is 5 million (1987).
therapies which are opposite to disease as well as etiological factors (Vyadhi-Hetu Pratidwandwi) because the attributes of Dosha resembles the etiological factors which vitiate the Dosha.
Various types of Avarana (layer) should be considered into the pathogenesis. Avarana is mainly of three types, viz., 1 
Materials and Methods
This clinical study is registered in the Clinical Trial Registry of India, ICMR, New Delhi (CTRI; www.ctri. nic.in) vide CTRI/2011/09/002003 and explained as per the Consolidated Standards of Reporting Trials statement 2010. [11] A total of 112 clinically diagnosed patients of Amlapitta attending outpatient and inpatient department of PG Hospital, Kayachikitsa at IPGT and RA, Gujarat Ayurved University, Jamnagar, were registered for this study. Out of 112, five patients were dropped out for several reasons.
Criteria for diagnosis Subjective criteria
A total of 112 patients were diagnosed and confirmed by the presence of Pratyatma Niyata Lakshana (cardinal features) [12] of Patients of Kaphaja Amlapitta will be diagnosed by the presence of the symptoms [13, 14] such as Aruchi, Gaurava, Jadyata, Kaphanisthivana (expectoration of thick phlegm), Lepa (coating of tongue), Sada (Lassitude), Sheeta (coldness), Vami (vomiting) and Kandu (itching sensation) whereas Pittaja Amlapitta will be diagnosed by the presence of the symptoms [14, 15] such as Nanavidha Pravritti (fluids eliminated through rectum with different colors), Trishna (excessive thirst), Hrit-Kantha-Kukshi Daha (burning sensation in chest, throat, and abdomen), Murccha (fainting), Bhrama (giddiness), Moha (delusion), Anala Sada (poor digestive power), Hrillasa (nausea), Sweda (excessive sweating) and Anga Peetata (yellowish discoloration of the skin).
Objective criteria
Out of 112, five patients were dropped out for several reasons. The objective criteria were taken; however, to exclude other pathological conditions, the following investigations were carried out (a) blood: total leukocyte count (TLC), differential leukocyte count (DLC), hemoglobin percentage (HB%), erythrocyte sedimentation rate (ESR), fasting blood sugar (FBS), liver function tests (LFT), lipid profile (b) stool: routine microscopic examination of the stool and (c) urine: routine examination.
Criteria for selection of patients
Inclusion criteria 
Exclusion criteria
(1) Patients with peptic ulcer, duodenal ulcer, carcinoma stomach, cardiac disorders. (2) Taking medicines for any other diseases such as hypertension, diabetes mellitus, ischemic heart diseases and chronic renal failure.
Plan of study
Clinically diagnosed 34 cases of Kapha predominant Amlapitta were allocated in Group A and 39 patients of Pitta predominant Amlapitta were allocated in Group B whereas 39 patients were allocated in Group C irrespective of their Doshik predominance. Shunthikhanda granules was administered to the patients of Group A, Vasakhanda Kushmandaka granules were given to the patients of Group B and one of these two drugs was administered randomly to the patients of Group C.
Further, the patients who were randomly treated with Shunthikhanda granules, allocated in Group C-1 and the patients who were randomly treated with Vasakhanda Kushmandaka granules were allocated in Group C-2 to observe the comparative effectiveness of drugs in between the groups where patients were treated according to Doshik predominance and without Doshik predominance, respectively. All patients of three groups were administered their recommended drug in a dose of 5 g, orally, twice a day, in between food with water for a period of 30 days. Computer-generated randomization [16] from www.randomization.com vide seed 18,135 created on Tuesday; January 03, 2012, at 2:12:18 PM was used for the clinical study.
Criteria for assessment
In this study, an effort has been made to follow the guidelines laid down by Acharya Charaka for the assessment of results. Having close acquaintance with the various states of the disease, such therapies should be prescribed which may help attainment of the four-fold blessings (Chatuhshreya). [17] Amlapitta symptoms rating scale (ASRS) was adopted to assess the relief in each symptom in Amlapitta patients. The ASRS is 20 items based on Rogabala, Agnibala, Dehabala, and Chetasabala; a disease-specific instrument used to evaluate symptoms of Amlapitta. The items are measured on a 5-point Likert-type scale [18] ranging from 0 = "no discomfort" to 4 = "very severe discomfort." The ASRS was administered at baseline and after the end of 30 days' clinical trial.
Total 100 scores were divided into Rogabala, Dehabala, Agnibala and Chetasabala. Thirty-five scores allotted for "Rogabala" were subdivided into seven items such as Hrit-Kantha-Daha, Tiktamlodgara, Vami, Gaurava, Utklesha, Shula and Brahma for the assessment of the severity of symptoms of Amlapitta. Twenty-five scores allotted for "Agnibala" were subdivided into five items such as Abhyavaharana Shakti (capacity of ingestion of food), Jarana Shakti (power of digestion), Avipaka and Aruchi for the assessment of power of digestion in Amlapitta. Twenty scores allotted for "Dehabala" were distributed into four items, viz., Balavriddhi (strength), Klama, Swara-Varna Yoga (clarity in voice and luster) and Sharira Upachaya (weight gain) for the assessment of bodily strength in Amlapitta. Twenty scores allotted for "Chetasabala" were subdivided into four items such as Nidra Labho Yathakalam (regularity in sleep), "Sukhena Cha Pratibodhanam" (feeling of well-being), "Vaikarikanam Cha Swapnana Darshanam"(uncomfortable dreams) and "Mano Buddhi Indriya Avyapatti" for the assessment of strength of mental faculties in Amlapitta.
Statistical analysis
The data obtained on the basis of observations were subjected to statistical analysis by applying Sigmastat 3.5 software (Software is now based in San Jose, California) in terms of mean, percentage, standard deviation, and standard error. The t-test and P values were calculated by using paired t-test and unpaired t-test considered at the level of P ≥ 0.05 (insignificant), P ≥ 0.002 to ≤ 0.04 (significant), and P ≤ 0.001 (highly significant).
Assessment of overall effect of therapy
For the overall assessment of the therapy, following five categories were taken into consideration:
• Complete remission-100% relief in the clinical signs and symptoms • Marked improvement-76%-99% relief in the clinical signs and symptoms
• Moderate improvement-51%-75% relief in the clinical signs and symptoms • Mild improvement-26-50% relief in the clinical signs and symptoms • Unchanged-Below 25% relief in the clinical signs and symptoms.
Follow-up study
After completion of due course of treatment, all the patients were requested to report for follow-up study for 1 week. During this period, no medicine was provided to the patients and recurrence of any symptoms regarding Rogabala, Dehabala, Agnibala and Chetasabala as well as impact of therapies on quality of life were observed.
Observations
Epidemiological data observed among 112 patients of Amlapitta was exhibited in Graph 
Effect of therapy Rogabala
Shunthikhanda granules in Group A and C-1 and Vasakhanda Kushmandaka granules in Group B and C-2 provided highly significant relief (P < 0.001) in the symptoms of Utklesha, Tiktamlodgara, Gaurava and Angasada, Hrit-Kantha Daha, Chardi and Shula. On Brahma, Shunthikhanda granules in Group A provided highly significant relief (P < 0.001) and in Group C-1 provided significant relief (P < 0.05) whereas Vasakhanda Kushmandaka granules provided significant relief in Group B (P = 0.002) and Group C-2 (P < 0. 
Comparative effect of therapy Rogabala
In comparison between Group A and Group C-1 [ Table 1 ], both showed statistically insignificant improvements with P > 0.05, except in Gaurava and Shula; therapeutic effect was statistically significant with P < 0.05. In comparison between Group B and Group C-2 [ Table 2 ], both showed statistically insignificant improvements with P > 0.05. In comparison between Group C-1 and Group C-2 [ Table 3 ], both showed statistically insignificant improvements with P > 0.05.
Agnibala
In comparison between Group A and Group C-1 [ Table 4 ], both showed improvements which were statistically highly significant with P < 0.001 in Abhyavaharana Shakti, Jarana Shakti and Aruchi. The effect was statistically insignificant on Avipaka and Vata-Mutra Retasam Mukti with P > 0.05. In comparison between Group B and Group C-2 [ Table 5 ], both showed statistically insignificant improvement with P > 0.05.
Dehabala
In comparison between Group A and Group C-1 [ Table 7 ] but significant on Mano Buddhi Indriya Avyapatti with P < 0.05 and highly significant on Sukhena Cha Pratibodhanam (P < 0.001). In comparison between Group B and Group C-2 [ Table 8 ], both showed statistically insignificant improvements with P > 0.05.
Comparison of overall effects as well as average relief of therapies
Regarding overall effect of therapy, marked positive improvement in Group A was 35.29%, in Group B, 26.47%, in Group C-1, 23.08% and Group C-2, 16.67%. Moderate improvement in Group A was 52.94%, in Group B, 58.82%, in Group C-1, 42.86% and in C-2, 61.11% whereas mild No improvement was observed only in Group C-1 (4.76%) and C-2 (5.56%). Complete remission (2.56%) was observed only in Group C-2 (5.56%) [ Table 9 ].
Average relief of Group A and Group B where Shunthikhanda and Vasakhanda Kushmandaka granules were given according to Doshik predominance was far better (68.78% and 65.4%, respectively) than that of Group C-1 and C-2 (60.40% and 64.46%) where Shunthikhanda and Vasakhanda Kushmandaka granules were given randomly without any doshik predominance [ Table 10 ].
After 1 week of follow-up, lesser incidence of recurrence of disease was reported in Group A (14.71%) and Group B (20.59%) rather than Group C-1 (33.33%) and Group C-2 (22.22%). Shunthikhanda granules in Group A exert a more sustained effect than Vasakhanda Kushmandaka granules in Group B on patients of Amlapitta even after discontinuation of the drug for 1-week follow-up [ Average relief of the patients (in Group A and B) whom medicines were given according to Doshik predominance was far better (68.78% and 65.4%) than the patients (in Group C-1 and C-2) where medicines were given randomly without any doshik predominance (60.40% and 64.46%, respectively).
The Phalashruti is that the vitiated Dosha, alleviated by Langhana and Pachana, may be aggravated at any time, but those who are eliminated by proper Samshodhana therapies do not recur further. [19] However, in this study, we knowingly had to ignore Aptopadesha to compromise on patients' preference and it was reflected on recurrence of the disease which was observed more in the patients of Group C-1 (33.33%) and C-2 (22.22%) than of Group A (14.71%) and Group B (20.59%).
Conclusion
In the era of rapid civilization, Amlapitta evolves as the most developing lifestyle disorder where Pitta and Kapha take pivot role associated with Vata in etiopathogenesis of Amlapitta. Amlapitta adversely affects the quality of life of patients, making it difficult to make dietary choices and causing sleep loss even hampering social life and contributes to a higher medical cost. The long-term effects can also lead to poorer quality of life. Diagnosis of the disease and treatment (Dosha-Dushya Vighatana) on the basis of Doshik predominance proved beneficial in this study.
Financial support and sponsorship
The study was supported by IPGT and RA, Gujarat Ayurved University, Jamnagar, Gujarat, India. 
